PATENT CLAIM ANALYSIS

Application Number: 16036670
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-05
Patent Classification: ["514", "050000"]

Abstract:
Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.

Claim (Index 8):
A method of treating or eradicating an HIV infection, comprising:\n a) reducing viral loads in a patient by administering a combination of HAART and a JAK inhibitor as claimed in  claim 1 , b) administering a reactivation agent, while maintaining one or both of HAART and JAK inhibitor therapy, c) withdrawing treatment with the reactivation agent, upon assessment of increased viral loads in the periphery that may be coupled with but not limited to assessment of diminished or absent memory lymphocytes with flow cytometry, while continuing treatment with HAART and one or more JAK inhibitors, until low level or absent viremia is maintained, d) withdrawing HAART, while JAK inhibitor therapy is maintained, or withdrawing both HAART and JAK inhibitor therapy, optionally while monitoring viral rebound.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 95.0
- Lexical Diversity: 1.7027
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14360905', '14808860', '13293828', '14512262', '12784916']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7095703518137572
- 35 USC 102 Novelty (BERT): 0.6661784132670878
- Combined Prediction Score: 0.7052311579590902
- Mean Citation Score: 448.166796
- Max Citation Score: 695.8886
- Similarity Product: 609.9332580912353

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test